In this issue:
Immune escape of relapsed AML cells after allogeneic HSCT
Lymphopenia and infection and associated death risk
Fixed duration venetoclax-rituximab in relapsed/refractory CLL
Cause of death in follicular lymphoma in the rituximab era
Need for arsenic trioxide in newly diagnosed APL
Real-world outcomes of pomalidomide for relapsed AL amyloidosis
Adding hydroxycarbamide to aspirin for non-high-risk essential thrombocythaemia
Dose-adjusted EPOCH-R for aggressive B-cell lymphoma with MYC rearrangement
EBV/LMP-specific T-cells in EBV lymphomas after allogeneic HSCT
Please login below to download this issue (PDF)